Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(3)

Phase 3(2)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06690905Phase 4Completed

Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity

Role: lead

NCT03862170Phase 3Terminated

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

Role: lead

NCT03424694Not ApplicableCompleted

HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer

Role: lead

NCT04756895Not ApplicableCompleted

Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population

Role: lead

NCT04043468Not ApplicableWithdrawn

Audit and Feedback Interventions With Primary Care Nursing Teams

Role: lead

NCT04075955Phase 3Completed

Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy

Role: lead

NCT02045030Phase 2Terminated

Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer

Role: lead

All 7 trials loaded